BAX Price Prediction Next Week
Technical Analysis: BAX is currently trading at $30.82, showing a slight increase of 0.65% in the last trading session. The stock has formed a series of higher lows and higher highs over the past week, indicating a potential short-term uptrend.
News Impact:
- Baxter recently declared a quarterly cash dividend of $0.17 per share, payable on April 1, 2025. The indicated annual dividend rate is $0.68 per share, representing a yield of 2.21%.
- The company is scheduled to report earnings on February 20, 2025, which could significantly impact price movement.
Price Projection for Next Week: Based on technical analysis and recent price action:
- Support levels: $30.61 (recent low)
- Resistance levels: $31.09 (recent high)
Expected price range for next week:
- Bullish scenario (40% probability): $31.50-$32.00
- Neutral scenario (45% probability): $30.50-$31.20
- Bearish scenario (15% probability): $29.80-$30.40
Trading Recommendation: SELL with a target price of $30.40. The rationale includes:
- The stock is trading near the upper end of its recent range
- RSI indicates slightly overbought conditions
- Pre-earnings uncertainty could lead to profit-taking
- The stock remains in a longer-term downtrend, down 22.25% over the past year
Set stop-loss at $31.30 to limit potential losses if the bullish momentum continues.
Key Metrics:
- P/E Ratio: 123.28 (significantly above industry average)
- Market Cap: $15.74B
- Beta: 0.61 (lower volatility compared to market)
- 52-Week Range: $28.34 - $44.01
Morningstar analysts rate Baxter as significantly undervalued with a fair value uncertainty rating of "High", suggesting potential long-term value despite near-term technical weakness.
BAX Similar Chart Price Prediction
The price of BAX is predicted to go up 0.38%, based on the high correlation periods with KT. The similarity of these two price pattern on the periods is 97%.
BAX
KT
Up: 0.38%Similarity: 97%
BAX Revenue Forecast
BAX EPS Forecast
BAX FAQs
What is bull’s view on BAX?
What is bear's view on BAX?
What is BAX revenue forecast for next quarter？
What is BAX eps forecast for next quarter？
BAX VS S&P500
In the long run, Baxter should continue to grow at a decent clip, primarily around evolutionary innovation in all of the major business lines and moderate pricing or mix improvements.
Emerging markets are a prime source of growth for many of Baxter's products, especially its peritoneal dialysis and nutrition solutions.
The company continues to strive toward higher margins, which may help earnings grow faster than sales, especially after key contracts have been renegotiated for 2025 and beyond.
BAX Analyst's Forecast
Joanne Wuensch
Citigroup
Hold
2024-12-11
Price Target
$37 → $35
Upside
+13.21%
Citi analyst Joanne Wuensch lowered the firm's price target on Baxter to $35 from $37 and keeps a Neutral rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Rick Wise
Stifel
Strong Buy
2024-11-11
Price Target
$46 → $38
Upside
+11.39%
Joanne Wuensch
Citigroup
Hold
2024-10-01
Price Target
$38 → $40
Upside
+8.37%
